COST-EFFECTIVENESS ANALYSIS OF ANLOTINIB AS A THIRD-LINE OR FURTHER TREATMENT IN ADVANCED NON-SMALL LUNG CANCERJ. HuangVALUE IN HEALTH(2020)引用 1|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要